Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

[1]  N. Kröger,et al.  Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression , 2020, Bone Marrow Transplantation.

[2]  N. Kröger,et al.  Conditioning‐based outcomes after allogeneic transplantation for myeloma following a prior autologous transplant (1991‐2012) on behalf of EBMT CMWP , 2019, European journal of haematology.

[3]  J. Kanda,et al.  Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome , 2019, British journal of haematology.

[4]  M. Kharfan-Dabaja,et al.  What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? , 2019, Bone Marrow Transplantation.

[5]  N. Kröger,et al.  Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents , 2018, Bone Marrow Transplantation.

[6]  C. Craddock,et al.  Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia , 2018, Bone Marrow Transplantation.

[7]  J. Lipton,et al.  Outcome following second allogeneic hematopoietic cell transplantation: A single‐center experience , 2018, European journal of haematology.

[8]  L. Kanz,et al.  Follow‐up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation , 2017, Clinical transplantation.

[9]  S. Parmar,et al.  Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  D. Weisdorf.  The role of second transplants for leukemia. , 2016, Best practice & research. Clinical haematology.

[11]  J. Gribben,et al.  Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes , 2016, Bone Marrow Transplantation.

[12]  J. Wagner,et al.  Second allogeneic hematopoietic cell transplantation for graft failure: Poor outcomes for neutropenic graft failure , 2015, American journal of hematology.

[13]  N. Kröger,et al.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.

[14]  C. Solano,et al.  Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients , 2015, Leukemia & lymphoma.

[15]  M. Pasquini,et al.  Second unrelated donor hematopoietic cell transplantation for primary graft failure. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  G. Mufti,et al.  Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant , 2008, Bone Marrow Transplantation.

[17]  M. Tallman,et al.  Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant , 2004, Bone Marrow Transplantation.

[18]  Cahn,et al.  Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) , 2000, British journal of haematology.

[19]  K. Kishi,et al.  Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: results of a survey of 66 cases in 24 Japanese institutes , 1997, Bone Marrow Transplantation.

[20]  J. Radich,et al.  Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Krishnan,et al.  Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  N. Kröger,et al.  Prevention and treatment of relapse after stem cell transplantation by cellular therapies , 2018, Bone Marrow Transplantation.

[23]  D. Porter,et al.  Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies , 2018, Bone Marrow Transplantation.

[24]  R. Fanin,et al.  Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.